dc.contributor.author | Castelo-Branco, L | |
dc.contributor.author | Tsourti, Z | |
dc.contributor.author | Gennatas, S | |
dc.contributor.author | Rogado, J | |
dc.contributor.author | Sekacheva, M | |
dc.contributor.author | Viñal, D | |
dc.contributor.author | Lee, R | |
dc.contributor.author | Croitoru, A | |
dc.contributor.author | Vitorino, M | |
dc.contributor.author | Khallaf, S | |
dc.contributor.author | Šušnjar, S | |
dc.contributor.author | Soewoto, W | |
dc.contributor.author | Cardeña, A | |
dc.contributor.author | Djerouni, M | |
dc.contributor.author | Rossi, M | |
dc.contributor.author | Alonso-Gordoa, T | |
dc.contributor.author | Ngelangel, C | |
dc.contributor.author | Whisenant, JG | |
dc.contributor.author | Choueiri, TK | |
dc.contributor.author | Dimopoulou, G | |
dc.contributor.author | Pradervand, S | |
dc.contributor.author | Arnold, D | |
dc.contributor.author | Harrington, K | |
dc.contributor.author | Michielin, O | |
dc.contributor.author | Dafni, U | |
dc.contributor.author | Pentheroudakis, G | |
dc.contributor.author | Peters, S | |
dc.contributor.author | Romano, E | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2022-07-13T14:01:55Z | |
dc.date.available | 2022-07-13T14:01:55Z | |
dc.date.issued | 2022-05-08 | |
dc.identifier | 100499 | |
dc.identifier | S2059-7029(22)00119-3 | |
dc.identifier.citation | ESMO Open, 2022, 7 (3), pp. 100499 - | |
dc.identifier.issn | 2059-7029 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5226 | |
dc.identifier.eissn | 2059-7029 | |
dc.identifier.eissn | 2059-7029 | |
dc.description.abstract | BACKGROUND: ESMO COVID-19 and CAncer REgistry (ESMO-CoCARE) is an international collaborative registry-based, cohort study gathering real-world data from Europe, Asia/Oceania and Africa on the natural history, management and outcomes of patients with cancer infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). PATIENTS AND METHODS: ESMO-CoCARE captures information on patients with solid/haematological malignancies, diagnosed with coronavirus disease 2019 (COVID-19). Data collected since June 2020 include demographics, comorbidities, laboratory measurements, cancer characteristics, COVID-19 clinical features, management and outcome. Parameters influencing COVID-19 severity/recovery were investigated as well as factors associated with overall survival (OS) upon SARS-CoV-2 infection. RESULTS: This analysis includes 1626 patients from 20 countries (87% from 24 European, 7% from 5 North African, 6% from 8 Asian/Oceanian centres), with COVID-19 diagnosis from January 2020 to May 2021. Median age was 64 years, with 52% of female, 57% of cancer stage III/IV and 65% receiving active cancer treatment. Nearly 64% patients required hospitalization due to COVID-19 diagnosis, with 11% receiving intensive care. In multivariable analysis, male sex, older age, Eastern Cooperative Oncology Group (ECOG) performance status ≥2, body mass index (BMI) <25 kg/m2, presence of comorbidities, symptomatic disease, as well as haematological malignancies, active/progressive cancer, neutrophil-to-lymphocyte ratio (NLR) ≥6 and OnCovid Inflammatory Score ≤40 were associated with COVID-19 severity (i.e. severe/moderate disease requiring hospitalization). About 98% of patients with mild COVID-19 recovered, as opposed to 71% with severe/moderate disease. Advanced cancer stage was an additional adverse prognostic factor for recovery. At data cut-off, and with median follow-up of 3 months, the COVID-19-related death rate was 24.5% (297/1212), with 380 deaths recorded in total. Almost all factors associated with COVID-19 severity, except for BMI and NLR, were also predictive of inferior OS, along with smoking and non-Asian ethnicity. CONCLUSIONS: Selected patient and cancer characteristics related to sex, ethnicity, poor fitness, comorbidities, inflammation and active malignancy predict for severe/moderate disease and adverse outcomes from COVID-19 in patients with cancer. | |
dc.format | Print-Electronic | |
dc.format.extent | 100499 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER | |
dc.relation.ispartof | ESMO Open | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | COVID-19 | |
dc.subject | SARS-CoV-2 | |
dc.subject | cancer | |
dc.subject | oncology | |
dc.title | COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE). | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-04-23 | |
dc.date.updated | 2022-07-13T13:57:00Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1016/j.esmoop.2022.100499 | |
rioxxterms.licenseref.startdate | 2022-05-08 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35644101 | |
pubs.issue | 3 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.organisational-group | /ICR/ImmNet | |
pubs.publication-status | Published online | |
pubs.volume | 7 | |
icr.researchteam | Targeted Therapy | |
dc.contributor.icrauthor | Harrington, Kevin | |
icr.provenance | Deposited by Mr Arek Surman on 2022-07-13. Deposit type is initial. No. of files: 1. Files: COVID-19 in patients with cancer first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE).pdf | |